1921
Volume 91, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Overexpression of interleukin-6 (IL-6) and IL-10 in endemic Burkitt lymphoma (eBL) may facilitate tumorigenesis by providing a permissive cytokine milieu. Promoter polymorphisms influence interindividual differences in cytokine production. We hypothesized that children genetically predisposed for elevated cytokine levels may be more susceptible to eBL. Using case-control samples from western Kenya consisting of 117 eBL cases and 88 ethnically matched healthy controls, we tested for the association between eBL risk and IL-10 (rs1800896, rs1800871, and rs1800872) and IL-6 (rs1800795) promoter single nucleotide polymorphisms (SNPs) as well as IL-10 promoter haplotypes. In addition, the association between these variants and Epstein Barr Virus (EBV) load was examined. Results showed that selected IL-10 and IL-6 promoter SNPs and IL-10 promoter haplotypes were not associated with risk eBL or EBV levels in EBV-seropositive children. Findings from this study reveal that common variants within the IL-10 and IL-6 promoters do not independently increase eBL risk in this vulnerable population.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.13-0616
2014-09-03
2017-09-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/91/3/649.html?itemId=/content/journals/10.4269/ajtmh.13-0616&mimeType=html&fmt=ahah

References

  1. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I, , 1993. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 5: 5661.[Crossref]
  2. Brady G, MacArthur GJ, Farrell PJ, , 2007. Epstein-Barr virus and Burkitt lymphoma. J Clin Pathol 60: 13971402.
  3. Bishop PC, Rao VK, Wilson WH, , 2000. Burkitt's lymphoma: molecular pathogenesis and treatment. Cancer Invest 18: 574583.[Crossref]
  4. Rainey JJ, Omenah D, Sumba PO, Moormann AM, Rochford R, Wilson ML, , 2007. Spatial clustering of endemic Burkitt's lymphoma in high-risk regions of Kenya. Int J Cancer 120: 121127.[Crossref]
  5. Bornkamm GW, , 2009. Epstein-Barr virus and the pathogenesis of Burkitt's lymphoma: more questions than answers. Int J Cancer 124: 17451755.[Crossref]
  6. Orem J, Mbidde EK, Lambert B, de Sanjose S, Weiderpass E, , 2007. Burkitt's lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci 7: 166175.
  7. Iversen OH, Iversen U, Ziegler JL, Bluming AZ, , 1974. Cell kinetics in Burkitt lymphoma. Eur J Cancer 10: 155163.[Crossref]
  8. Chêne A, Donati D, Guerreiro-Cacais AO, Levitsky V, Chen Q, Falk KI, Orem J, Kironde F, Wahlgren M, Bejarano MT, , 2007. A molecular link between malaria and epstein-barr virus reactivation. PLoS Pathog 3: e80.[Crossref]
  9. Epstein MA, , 1984. Burkitt's lymphoma: clues to the role of malaria. Nature 312: 398.[Crossref]
  10. Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B, Rosolowski M, Ammerpohl O, Wagener R, Bernhart S, Lenze D, Szczepanowski M, Paulsen M, Lipinski S, Russell R, Adam-Klages S, Apic G, Claviez A, Hasenclever D, Hovestadt V, Hornig N, Korbel J, Kube D, Langenberger D, Lawerenz C, Lisfeld J, Meyer K, Picelli S, Pischimarov J, Radlwimmer B, Rausch T, Rohde M, Schilhabel M, Scholtysik R, Spang R, Trautmann H, Zenz T, Borkhardt A, Drexler H, Möller P, MacLeod R, Pott C, Schreiber S, Trümper L, Loeffler M, Stadler P, Lichter P, Eils R, Küppers R, Hummel M, Klapper W, Rosenstiel P, Rosenwald A, Brors B, Siebert R, MMML-Seq Project ICGC; , 2012. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 44: 13161320.[Crossref]
  11. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards K, Dunphy C, Choi W, Srivastava G, Lugar P, Rizzieri D, Lagoo A, Bernal-Mizrachi L, Mann K, Flowers C, Naresh K, Evens A, Chadburn A, Gordon L, Czader M, Gill J, Hsi E, Greenough A, Moffitt A, McKinney M, Banerjee A, Grubor V, Levy S, Dunson D, Dave S, , 2012. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 44: 13211325.[Crossref]
  12. Howell WM, Rose-Zerilli MJ, , 2007. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr 137: 194S199S.
  13. Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, Rigal D, Warzocha K, Coiffier B, Salles G, , 2004. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 103: 35293534.[Crossref]
  14. Cooper M, Caligiuri M, , 2003. Cytokines and Cancer. The Cytokine Handbook (Fourth Edition). Elsevier Ltd., Academic Press, 12131232. ISBN: 978-0-12-689663-3.
  15. Ogden CA, Pound JD, Batth BK, Owens S, Johannessen I, Wood K, Gregory CD, , 2005. Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma. J Immunol 174: 30153023.[Crossref]
  16. Yokoi T, Miyawaki T, Yachie A, Kato K, Kasahara Y, Taniguchi N, , 1990. Epstein-Barr virus-immortalized B cells produce IL-6 as an autocrine growth factor. Immunology 70: 100105.
  17. Cordano P, Lake A, Shield L, Taylor GM, Alexander FE, Taylor PRA, White J, Jarrett RF, , 2005. Effect of IL-6 promoter polymorphism on incidence and outcome in Hodgkin's lymphoma. Br J Haematol 128: 493495.[Crossref]
  18. Benjamin D, Knobloch TJ, Dayton MA, , 1992. Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood 80: 12891298.
  19. Stewart JP, Behm FG, Arrand JR, Rooney CM, , 1994. Differential expression of viral and human interleukin-10 (IL-10) by primary B cell tumors and B cell lines. Virology 200: 724732.[Crossref]
  20. Cunningham LM, Chapman C, Dunstan R, Bell MC, Joske DJL, , 2003. Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 44: 251255.[Crossref]
  21. Liu J, Song B, Bai X, Liu W, Li Z, Wang J, Zheng Y, Wang Z, , 2010. Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese. BMC Cancer 10: 456.[Crossref]
  22. Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL, , 2003. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 88: 255259.[Crossref]
  23. Wang J, Ding Q, Shi Y, Cao Q, Qin C, Zhu J, Chen J, Yin C, , 2011. The interleukin-10-1082 promoter polymorphism and cancer risk: a meta-analysis. Mutagenesis 27: 305312.[Crossref]
  24. Gourley IS, Kurtis JD, Kamoun M, Amon JJ, Duffy PE, , 2002. Profound bias in interferon-γ and interleukin-6 allele frequencies in western Kenya, where severe malarial anemia is common in children. J Infect Dis 186: 10071012.[Crossref]
  25. Baran W, Szepietowski JC, Mazur G, Baran E, , 2008. IL-6 and IL-10 promoter gene polymorphisms in psoriasis vulgaris. Acta Derm Venereol 88: 113116.[Crossref]
  26. Ouma C, Davenport GC, Were T, Otieno MF, Hittner JB, Vulule JM, Martinson J, Ong'echa JM, Ferrell RE, Perkins DJ, , 2008. Haplotypes of IL-10 promoter variants are associated with susceptibility to severe malarial anemia and functional changes in IL-10 production. Hum Genet 124: 515524.[Crossref]
  27. Burkitt D, , 1962. A lymphoma syndrome in African children. Ann R Coll Surg Engl 30: 211219.
  28. Burkitt D, O'Conor G, , 1961. Malignant lymphoma in African children. I. A clinical syndrome. Cancer 14: 258269.[Crossref]
  29. Cozen W, Gill PS, Ingles SA, Masood R, Martínez-Maza O, Cockburn MG, Gauderman WJ, Pike MC, Bernstein L, Nathwani BN, Salam MT, Danley KL, Wang W, Gage J, Gundell-Miller S, Mack TM, , 2004. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood 103: 32163221.[Crossref]
  30. López RVM, Zago MA, Eluf-Neto J, Curado MP, Daudt AW, da Silva-Junior WA, Zanette DL, Levi JE, de Carvalho MB, Kowalski LP, Abrahão M, de Góis-Filho JF, Boffetta P, Wünsch-Filho V, , 2011. Education, tobacco smoking, alcohol consumption, and IL-2 and IL-6 gene polymorphisms in the survival of head and neck cancer. Braz J Med Biol Res 44: 10061012.[Crossref]
  31. Mulama DH, Bailey JA, Foley J, Chelimo K, Ouma C, Jura WGZO, Otieno J, Vulule J, Moormann AM, , 2014. Sickle cell trait is not associated with endemic Burkitt lymphoma: an ethnicity and malaria endemicity-matched case-control study suggests factors controlling EBV may serve as a predictive biomarker for this pediatric cancer. Int J Cancer 134: 645653.[Crossref]
  32. Moormann AM, Chelimo K, Sumba OP, Lutzke ML, Ploutz-Snyder R, Newton D, Kazura J, Rochford R, , 2005. Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect Dis 191: 12331238.[Crossref]
  33. Moormann AM, Chelimo K, Sumba PO, Tisch DJ, Rochford RA, Kazura JW, , 2007. Exposure to holoendemic malaria results in suppression of Epstein-Barr virus-specific T cell immunosurveillance in Kenyan children. J Infect Dis 195: 799808.[Crossref]
  34. Moormann AM, Lozada JS, , 2009. Burkitt lymphoma in Uganda: 50 years of ongoing discovery. Pediatr Blood Cancer 52: 433434.[Crossref]
  35. Caligiuri MA, Lotze MT, SpringerLink; , 2007. Cytokines in the Genesis and Treatment of Cancer. Totowa, NJ: Humana Press.[Crossref]
  36. Voorzanger N, Touitou R, Garcia E, Delecluse HJ, Rousset F, Joab I, Favrot MC, Blay JY, , 1996. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 56: 54995505.
  37. Mocellin S, Marincola FM, Young HA, , 2005. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 78: 10431051.[Crossref]
  38. da Silva GN, Bacchi MM, Rainho Cu A, de Oliveira DE, , 2007. Epstein-Barr virus infection and single nucleotide polymorphisms in the promoter region of interleukin 10 gene in patients with Hodgkin lymphoma. Arch Pathol Lab Med 131: 16911696.
  39. Minnicelli C, Barros MHM, Klumb CE, Romano SO, Zalcberg IR, Hassan R, , 2012. Relationship of Epstein-Barr virus and interleukin 10 promoter polymorphisms with the risk and clinical outcome of childhood Burkitt lymphoma. PLoS ONE 7: e46005.[Crossref]
  40. Whittle HC, Brown J, Marsh K, Greenwood BM, Seidelin P, Tighe H, Wedderburn L, , 1984. T-cell control of Epstein-Barr virus-infected B cells is lost during P. falciparum malaria. Nature 312: 449450.[Crossref]
  41. Tosato G, Tanner J, Jones KD, Revel M, Pike SE, , 1990. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol 64: 30333041.
  42. Tanner J, Tosato G, , 1991. Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest 88: 239247.[Crossref]
  43. Biron CA, Brossay L, , 2001. NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol 13: 458464.[Crossref]
  44. Helminen M, Lahdenpohja N, Hurme M, , 1999. Polymorphism of the interleukin-10 gene is associated with susceptibility to Epstein-Barr virus infection. J Infect Dis 180: 496499.[Crossref]
  45. Liu Y, de Waal Malefyt R, Briere F, Parham C, Bridon JM, Banchereau J, Moore KW, Xu J, , 1997. The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. J Immunol 158: 604613.
  46. Zeidler R, Eissner G, Meissner P, Uebel S, Tampé R, Lazis S, Hammerschmidt W, , 1997. Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood 90: 23902397.
  47. Ogwang MD, Bhatia K, Biggar RJ, Mbulaiteye SM, , 2008. Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited. Int J Cancer 123: 26582663.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.13-0616
Loading
/content/journals/10.4269/ajtmh.13-0616
Loading

Data & Media loading...

Supplementary Data

Supplementary PDF

  • Received : 24 Oct 2013
  • Accepted : 30 Jun 2014

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error